Clinical trial · Interventional
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
A Multicenter, Open-Label Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
NCT00144495CI-TRIAL-00001960completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy Induced Anemia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| recombinant human erythropoietin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- patient whose ΔHb is less than 1.0g/dL on the day of 7th administration
- interventionNames
- Drug: recombinant human erythropoietin
- type
- EXPERIMENTAL
- label
- 2
- description
- patient whose ΔHb is 1.0g/dL or above on the day of 7th administration
- interventionNames
- Drug: recombinant human erythropoietin
Primary outcomes (1)
- measure
- The increase in Hb concentration
- timeFrame
- Day 28th or later
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: * Cancer patients Exclusion Criteria: * a history of myocardial, cerebral or pulmonary infarction * severe hypertension beyond control by drugs
References
Publications (0)
Data not yet available
No reference posted for this study.